Jasmin Bartl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jasmin Bartl has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Edna Grünblatt
Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland
5 shared publications - Peter Riederer
Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wuerzburg, University of Wuerzburg, Wuerzburg, Germany
3 shared publications - Hiroki Ozawa
Nagasaki University Graduate School of Biomedical Sciences
2 shared publications - Susanne Walitza
Department of Child and Adolescent Psychiatry, University Hospital of Psychiatry Zurich, Zurich, Switzerland
2 shared publications - Takatoshi Mori
Division of Neuropsychiatry, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
2 shared publications - Ana Knezovic
Department of Pharmacology and Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Salata 11, 10 000 Zagreb, Croatia
1 shared publication
Latest Publications
- Open Access
- 4 June 2015
- Published by Springer Nature in Journal of Molecular Psychiatry
- Vol. 3 (1) , 1-10
Characterization of cognitive deficits in spontaneously hypertensive rats, accompanied by brain insulin receptor dysfunction
The spontaneously hypertensive rat (SHR) has been used to model changes in the central nervous system associated with cognitive-related disorders. Recent human and animal studies indicate a possible relationship between cognitive deficits, insulin resistance and hypertension. We aimed to investigate whether cognitively impaired SHRs develop central and/or peripheral insulin resistance and how their cognitive performance is influenced by the animal’s sex and age as well as strains used for comparison (Wistar and Wistar-Kyoto/WKY). Three and seven-month-old SHR, Wistar, and WKY rats were studied for their cognitive performance using Morris Water Maze (MWM) and Passive Avoidance tests (PAT). Plasma glucose and insulin were obtained after oral glucose tolerance tests. Cerebral cortex, hippocampus, and striatum status of insulin-receptor (IR) β-subunit and glycogen synthase kinase-3β (GSK3β) and their phosphorylated forms were obtained via ELISA. SHRs performed poorly in MWM and PAT in comparison to both control strains but more pronouncedly compared to WKY. Females performed poorer than males and 7-month-old SHRs had poorer MWM performance than 3-month-old ones. Although plasma glucose levels remained unchanged, plasma insulin levels were significantly increased in the glucose tolerance test in 7-month-old SHRs. SHRs demonstrated reduced expression and increased activity of IRβ-subunit in cerebral cortex, hippocampus, and striatum with different regional changes in phospho/total GSK3β ratio, as compared to WKYs. Results indicate that cognitive deficits in SHRs are accompanied by both central and peripheral insulin dysfunction, thus allowing for the speculation that SHRs might additionally be considered as a model of insulin resistance-induced type of dementia.
- 4 June 2015
- Published by Springer Nature in Journal of Molecular Psychiatry
- Vol. 3 (1) , 1-10
Open AccessCharacterization of cognitive deficits in spontaneously hypertensive rats, accompanied by brain insulin receptor dysfunction
The spontaneously hypertensive rat (SHR) has been used to model changes in the central nervous system associated with cognitive-related disorders. Recent human and animal studies indicate a possible relationship between cognitive deficits, insulin resistance and hypertension. We aimed to investigate whether cognitively impaired SHRs develop central and/or peripheral insulin resistance and how their cognitive performance is influenced by the animal’s sex and age as well as strains used for comparison (Wistar and Wistar-Kyoto/WKY). Three and seven-month-old SHR, Wistar, and WKY rats were studied for their cognitive performance using Morris Water Maze (MWM) and Passive Avoidance tests (PAT). Plasma glucose and insulin were obtained after oral glucose tolerance tests. Cerebral cortex, hippocampus, and striatum status of insulin-receptor (IR) β-subunit and glycogen synthase kinase-3β (GSK3β) and their phosphorylated forms were obtained via ELISA. SHRs performed poorly in MWM and PAT in comparison to both control strains but more pronouncedly compared to WKY. Females performed poorer than males and 7-month-old SHRs had poorer MWM performance than 3-month-old ones. Although plasma glucose levels remained unchanged, plasma insulin levels were significantly increased in the glucose tolerance test in 7-month-old SHRs. SHRs demonstrated reduced expression and increased activity of IRβ-subunit in cerebral cortex, hippocampus, and striatum with different regional changes in phospho/total GSK3β ratio, as compared to WKYs. Results indicate that cognitive deficits in SHRs are accompanied by both central and peripheral insulin dysfunction, thus allowing for the speculation that SHRs might additionally be considered as a model of insulin resistance-induced type of dementia.
- 1 January 2014
- Published by Elsevier in Neuroscience Letters
- Vol. 559, 56-60
Enhancement of cell viability after treatment with polyunsaturated fatty acids
- 1 January 2014
- Published by Elsevier in Neuroscience Letters
- Vol. 559, 56-60
Enhancement of cell viability after treatment with polyunsaturated fatty acids
- 23 November 2013
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 121 (4) , 379-383
Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity
Patients with Parkinson’s disease receive selective irreversible monoamine oxidase (MAO)-B inhibitors, but their effects on MAO-A activity are not known during long-term application. We determined MAO-A inhibition in plasma samples from patients with MAO-B inhibitor intake or without MAO-B inhibitor treatment and from healthy controls. We detected a 70 % reduction of MAO-A activity in patients with MAO-B inhibitor therapy in comparison to the other groups. Our results suggest that treatment with MAO-B inhibitor may also influence MAO-A activity in vivo, when administered daily.
- 23 November 2013
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 121 (4) , 379-383
Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity
Patients with Parkinson’s disease receive selective irreversible monoamine oxidase (MAO)-B inhibitors, but their effects on MAO-A activity are not known during long-term application. We determined MAO-A inhibition in plasma samples from patients with MAO-B inhibitor intake or without MAO-B inhibitor treatment and from healthy controls. We detected a 70 % reduction of MAO-A activity in patients with MAO-B inhibitor therapy in comparison to the other groups. Our results suggest that treatment with MAO-B inhibitor may also influence MAO-A activity in vivo, when administered daily.
- Open Access
- 23 April 2013
- Published by Springer Nature in Journal of Molecular Psychiatry
- Vol. 1 (1) , 1-5
Methylphenidate enhances neural stem cell differentiation
The psychostimulant methylphenidate (MPH) is the first choice of drug treatment in Attention-Deficit/Hyperactivity Disorder (ADHD). Since therapy often begins at a time when the brain is still developing and the long-term consequences of MPH are still not fully clarified, we examined the influences of an acute treatment with MPH on the differentiation and proliferation of murine neural stem cells (mNSC). We found that MPH enhanced neuronal differentiation and inhibited neural proliferation.
- 23 April 2013
- Published by Springer Nature in Journal of Molecular Psychiatry
- Vol. 1 (1) , 1-5
Open AccessMethylphenidate enhances neural stem cell differentiation
The psychostimulant methylphenidate (MPH) is the first choice of drug treatment in Attention-Deficit/Hyperactivity Disorder (ADHD). Since therapy often begins at a time when the brain is still developing and the long-term consequences of MPH are still not fully clarified, we examined the influences of an acute treatment with MPH on the differentiation and proliferation of murine neural stem cells (mNSC). We found that MPH enhanced neuronal differentiation and inhibited neural proliferation.
- Open Access
- 1 January 2013
- Published by Springer Nature in Journal of Molecular Psychiatry
- Vol. 1 (1) , 10
Correction: Methylphenidate enhances neural stem cell differentiation
- 1 January 2013
- Published by Springer Nature in Journal of Molecular Psychiatry
- Vol. 1 (1) , 10
Open AccessCorrection: Methylphenidate enhances neural stem cell differentiation